CHMP anså det også for nødvendigt at vurdere hele rapporten om analysen af sammenligneligheden mellem Rapinyl og Actiq, eftersom de tilgængelige PK- data ikke kunne understøtte ligheden mellem de to produkter.
The CHMP also considered it necessary to assess the full report of the analysis on the comparability of Rapinyl and Actiq, as the available PK data could not support the similarity of both products.